Charles Cardon


Charles Cardon

National Partner

Paris | 32 rue de Monceau, Paris, France 75008
+33 1 57 57 80 77 | +33 1 57 57 80 81

| vCard | PDF

Charles Cardon practices in the areas of corporate and financial law, with a focus on takeovers, M&A, capital market and private equity transactions. Mr. Cardon has significant experience in France, in the U.S. and in Latin America assisting companies in their external growth projects.

Mr. Cardon has developed a high level of experience in advising funds in a wide range of transactions including LBO and stock exchange related deals, such as acquisition of a public target company by way of PtoP and IPO exit. He advises public companies in the context of their takeover bids (as advisor of target companies, bidders or shareholders); issuance of securities, governance matters, disclosure requirements and relationship with shareholders as well as corporate law matters.

Mr. Cardon is widely published and is a visiting professor at the Sorbonne-Assas International Law School on issues pertaining to international takeovers, company law and securities law.

Mr. Cardon is recognized for France: Capital Markets ‒ Equity; M&A; and Private Equity by IFLR1000, 2019.

Prior to joining Dechert, Mr. Cardon served as counsel in the corporate group of a leading law firm. His previous experience also includes spending six years in the Paris and New York offices of another Tier 1 international law firm, where he developed his practice on private equity deals and M&A transactions for French and international companies.


Private Equity deals and venture capital deals:

  • Advising Astorg on its investment into Echosens (2018).
  • Advising Five Arrows on the acquisition of A2Mac1 (2017).
  • Advising the founder and the company on the investment of Partech Ventures into Sendinblue (2017).
  • Advising the managers on the secondary LBO of In'Tech Medical by Eurazeo PME from TCR Capital (2017).
  • Advising a PE fund on the acquisition of a leading player in the business-to-business information and services (2016).
  • Advising several PE funds on the disposal of a leading player in the field of European medical biology laboratory (2015).

M&A transactions

Public M&A transactions:            

  • Advising Generali on its majority investment and strategic partnership with Sycomore Asset Management (2019).
  • Advising Eurovia on its acquisition of the assets of Lane Plants and Paving (2018). 
  • Advising the seller on the sale of NHCO to Chiesi (2018). 
  • Advising an oil company specialising in the production of hydrocarbons on the acquisition of Venezuelan assets (2015). 
  • Advising an insurance group on its strategic partnership with a French bank (2015).


  •  Advising Vexim and its shareholders on the takeover of Stryker Corporation (2017).
  •  Advising the Medtech founder and the controlling shareholders on the takeover of Zimmer Biomet (2016). 
  • Advising a global leader in digital transformation on its takeover of an European Cyber Security expert (2014).

Advising controlling shareholders on IPOs:     

  • Advising a French multinational electric utility company on the IPO (2014). 
  • Advising a global leader in digital transformation on the IPO (2014). 

Block trade sale/ABB/Reserved share capital increase

  • Advising Equitis on the acquisition of a block of shares of Emova (2016). 
  • Advising VINCI on the investment by way of reserved share capital increase, into Constructora Conconcreto (2015). 

Capital market transaction:

  • Advising an agricultural company on the issuance of new bonds in the restructuring of its financial debt (2015).

    Includes matters handled at Dechert or prior to joining the firm
  • Université Paris 1 Panthéon-Sorbonne, Master 1, 2003
  • Université Paris 1 Panthéon-Sorbonne, Master 2, 2004
  • ESSEC Business School, 2004
  • Paris
  • French
  • English
  • Spanish
Speaking Engagements
  • Règlement Abus de Marché / Information privilégiée by Dechert LLP - Paris (April 27, 2017)